Patent ID: 9051386
Filing Date: 2015-06-09
Classification: A61K,A61P,C07K,Y02A

Abstract:
1. A method of reducing T-lymphocyte mediated inflammation in a subject comprising: administering a therapeutically effective amount of a human immunosuppressant protein (HISP) to the subject, wherein the HISP protein is obtained by: a) growing a culture of hNT neuronal cells; b) obtaining supernatant from the hNT cell culture; c) concentrating the supernatant; d) exposing the supernatant to gel electrophoresis to produce isoelectric fractions; e) collecting a peak immunosuppressive active isoelectric fraction; and f) collecting the protein extract from the fraction; and wherein the HISP protein has an isoelectric point of about 4.8, a molecular weight of between about 40-100 kDa and exhibits at least one immunosuppressive activity selected from the group consisting of suppressed T-cell activation, suppressed T-cell proliferation, and suppressed production of IL-2 by T-cells.